[JPI Seminar] MHLW: "Building a Drug Discovery Ecosystem and Promoting Clinical Trials" to be held on Thursday, April 9

Key facts

  • [JPI Seminar] MHLW: "Building a Drug Discovery Ecosystem and Promoting Clinical Trials" to be held on Thursday, April 9
  • JPI invites Mr. Yasuhiro Araki from the Ministry of Health, Labour and Welfare to host a seminar on building a drug discovery ecosystem and promoting clinical trials.
  • Date: March 29, 2026

Direct answer

JPI invites Mr. Yasuhiro Araki from the Ministry of Health, Labour and Welfare to host a seminar on building a drug discovery ecosystem and promoting clinical trials.

Citation
[JPI Seminar] MHLW: "Building a Drug Discovery Ecosystem and Promoting Clinical Trials" to be held on Thursday, April 9 (March 29, 2026)
Source
PR Times
Date
March 29, 2026
JPI invites Mr. Yasuhiro Araki from the Ministry of Health, Labour and Welfare to host a seminar on building a drug discovery ecosystem and promoting clinical trials.
NQ 56/100

📋 Article Processing Timeline

  • 📰 Published: March 29, 2026 at 20:22
  • 🤖 AI Analyzed: May 26, 2026 at 21:27 (1393h 4m after Published)
JPI (Japan Planning Institute) will host a seminar featuring Mr. Yasuhiro Araki, Director of the Clinical Trial Promotion Office, Research and Development Policy Division, Health Policy Bureau, Ministry of Health, Labour and Welfare (MHLW), to provide a detailed explanation of policies for building a drug discovery ecosystem and promoting clinical trials.

[Details and Registration]: https://www.jpi.co.jp/seminar/17693

[Title]
The Growing "Drug Loss" Problem and Strengthening Japan's Drug Discovery Capabilities
MHLW: Building a Drug Discovery Ecosystem and Promoting Clinical Trials
- Regulatory harmonization and concrete measures to deliver the latest pharmaceuticals rapidly -

[Date and Time]
Thursday, April 9, 2026, 09:30 - 11:30
*Applications for archive streaming are accepted even after the seminar concludes.

[Lecturer]
Mr. Yasuhiro Araki
Director, Clinical Trial Promotion Office, Research and Development Policy Division, Health Policy Bureau, Ministry of Health, Labour and Welfare

[Lecture Overview]
In recent years, the issue of "drug loss"—pharmaceuticals approved in the West but not developed in Japan—has become prominent, raising concerns that innovative medicines may not be available to the Japanese public. In response, the public and private sectors are working together to: 1) strengthen Japan's drug discovery capabilities, 2) deliver the latest medicines to citizens rapidly, and 3) build a social system where a cycle of investment and innovation is sustained. This lecture will provide an overview of government initiatives to build a drug discovery ecosystem in Japan, as well as a detailed explanation of the current state of clinical trials and various measures being implemented by the MHLW to promote them.

[Lecture Agenda]
1. Current status of drug loss in Japan
2. Policies for building a drug discovery ecosystem in Japan
3. Current status and challenges of clinical trials in Japan
4. MHLW initiatives to promote clinical trials
5. Q&A
6. Business card exchange and networking session
This is a valuable opportunity unique to JPI seminars, allowing for direct dialogue and Q&A with the lecturer, as well as networking among attendees across different industries to gain practical insights and spark new collaborations.

FAQ

Who is the featured lecturer at the JPI seminar?

The featured lecturer is Mr. Yasuhiro Araki, Director of the Clinical Trial Promotion Office at the Ministry of Health, Labour and Welfare.

When and at what time is this seminar scheduled to be held?

The seminar is scheduled to take place on Thursday, April 9, 2026, from 09:30 to 11:30.

What is the main definition of the drug loss problem mentioned in the text?

The drug loss problem refers to pharmaceuticals that are approved in the West but not developed in Japan.

What are the three goals that the public and private sectors are working together to achieve?

The public and private sectors aim to strengthen Japan's drug discovery capabilities, deliver the latest medicines to citizens rapidly, and sustain a cycle of investment and innovation.

What are the main topics included in the agenda of the lecture?

The agenda includes the current status of drug loss, policies for building a drug discovery ecosystem, the status of clinical trials, MHLW initiatives, a Q&A session, and a business card exchange.